Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases

Written on Monday 12th October 2020

Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases

Independent symposium chaired by Dr Saul Karpen

With Dr Paul Dawson, Dr Kathleen Loomes, and Dr Arun Sanyal

Sunday November 15TH 2020 | 19:00 – 21:00 EST

Presentations

  1. Welcome & pre-activity information
    Dr Saul Karpen
  2. Ileal bile acid transport (IBAT) inhibitors: mechanism of action and physiological effects
    Dr Paul Dawson
  3. Potential therapeutic roles for IBAT inhibitors in cholestatic liver disease: a case of Alagille syndrome
    Dr Kathleen Loomes
  4. Potential therapeutic roles for IBAT inhibitors in metabolic liver disease: a case of NASH
    Dr Arun Sanyal
  5. IBAT inhibitors in clinical trials
    Dr Saul Karpen
  6. Panel discussion with interactive audience Q&A: what are the potential applications and possible pitfalls of IBAT inhibitors in clinical practice?
  7. Chair’s close
    Dr Saul Karpen

Audience

  • Primary Audience: Hepatologists/Pediatric Hepatologists, Gastroenterologists/Pediatric gastroenterologists
  • Secondary Audience: Transplant Surgeons

Learning objectives

After attending this symposium, learners will be able to:

  • Discuss the mechanism of action of ileal bile acid transporter (IBAT) inhibitors and their proposed effects on cholestatic liver disease and metabolic disease.
  • Describe the pathophysiological features of cholestatic liver diseases, as well as clinical outcomes associated with these conditions.
  • Describe the pathophysiological features of metabolic liver diseases, as well as clinical outcomes associated with these conditions.
  • Recall clinical trial data regarding the efficacy and safety of IBAT inhibitors in the treatment of cholestatic liver disease, including biliary atresia and progressive familial intrahepatic cholestasis (PFIC).

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Presented for attendees of The Liver Meeting Digital Experience™. This event is sponsored by Liberum IME and supported by Albireo Pharmaceuticals. This is not an official event of the American Association for the Study of Liver Diseases.